Table 3.
Primary and secondary outcomes of the propensity-matched comparison of patients treated with hydroxychloroquine versus patients not receiving hydroxychloroquine
| Patients receiving hydroxychloroquine (n=10 703) | Patients not receiving hydroxychloroquine (n=21 406) | Odds ratio (95% CI) | p value | |
|---|---|---|---|---|
| Primary outcome | ||||
| Developed active SARS-CoV-2 infection | 31 (0·3%) | 78 (0·4%) | 0·79 (0·52–1·20) | 0·27 |
| Secondary outcomes | ||||
| Hospital admission associated with SARS-CoV-2 infection | 9/31 (29·0%) | 19/78 (24·4%) | 1·27 (0·50–3·23) | 0·62 |
| Intensive care requirement associated with SARS-CoV-2 infection | 2/9 (22·2%) | 4/19 (21·1%) | 1·07 (0·16–7·31) | 0·99 |
| Mortality associated with SARS-CoV-2 infection | 0 | 7/78 (9·0%) | .. | 0·19 |
| Overall hospital admission | 343 (3·2%) | 733 (3·4%) | 0·93 (0·82–1·06) | 0·30 |
| Overall mortality | 88 (0·8%) | 251 (1·2%) | 0·70 (0·55–0·89) | 0·0031 |
Data are n (%) or n/N (%) unless otherwise stated. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.